Skip to main content
. Author manuscript; available in PMC: 2013 Dec 15.
Published in final edited form as: J Immunol. 2012 Nov 14;189(12):5590–5601. doi: 10.4049/jimmunol.1201744

Figure 3. CTLA-4 blockade decreases expression of IL-35 by antigen-specific CD8+CTLA-4+ T cells.

Figure 3

Samples from a patient with CTLA-4-regulated PAP-specific immune responses (ID002) were stimulated for 72 hours with PAP, PSA, or media alone in the presence of an anti-CTLA-4 antibody or an IgG control (PSA+IgG: grey, PSA+anti-CTLA-4: hatched gey, PAP+IgG: black, PAP+anti-CTLA-4: white hatched). Cells were then sorted via flow cytometry for the following populations: CD3+CD8+CTLA-4+ (panel A), CD3+CD8+CTLA-4− (panel B), or CD3+CD8− (panel C). Relative mRNA expression of IL-12A, Ebi3, IL-10, IL-12B, IL-23A, and IL-27 was determined by quantitative RT-PCR, and were normalized against the ribosomal protein P0 as an internal control and the media-alone cell-sorted sample. Differences between control IgG and anti-CTLA-4 treatment group means were calculated using a student’s t-test, with * indicating p≤0.05. Data shown is representative of three independent experiments.